Главная | Обратная связь | Поможем написать вашу работу!

7. Дополнительная информация (в том числе факторы, влияющие на исход заболевания или состояния)

7. Дополнительная информация (в том числе факторы, влияющие на исход заболевания или состояния)

Информация отсутствует.

Критерии оценки качества оценки медицинской помощи

N	Критерии качества	Уровень убедительности рекомендаций	Уровень достоверности доказательств
	Выявленные феномены систематизированы, проведена их психопатологическая квалификация	С
	Проведено экспериментально-психологическое (психодиагностическое) исследование	С
	Рекомендована консультация врача-невролога при указании в анамнезе на органические вредности (травмы головы, нейроинфекции, интоксикация ПАВ)	С
	Назначена лекарственная терапия антипсихотическими средствами (при наличии психотической симптоматики и отсутствии медицинских противопоказаний)	С
	Назначена лекарственная терапия ламотриджином (при наличии у лиц с пограничным расстройством личности импульсивности, агрессивности и отсутствии медицинских противопоказаний)	B
	Назначена лекарственная терапия препаратами группы " антидепрессанты" (при наличии тревожно-депрессивной симптоматики и отсутствии медицинских противопоказаний)	С
	Назначена лекарственная терапия циталопрамом или сертралином** (при наличии депрессивной симптоматики и отсутствии медицинских противопоказаний)	B
	Купирована острая психотическая симптоматика, психомоторное возбуждение	В
	Рекомендована долгосрочная психотерапия	А

______________________________

* Ст. 5 Закона о психиатрической помощи и гарантиях прав граждан при её оказании.

** Комментарий к ст. 16 Закона о психиатрической помощи и гарантиях прав граждан при её оказании

Список литературы

1. Смулевич А. Б. Расстройства личности. Рациональная фармакотерапия в психиатрической практике. Руководство для практикующих врачей. - М.: Литтера, 2014. - С. 458-493.

2. Смулевич А. Б. Расстройства личности. Психиатрия. Национальное руководство. - М.: ГЭОТАР-Медиа, 2018. - С. 663-668.

3. Рубинштейн С. Я. Экспериментальные методики патопсихологии и опыт применения их в клинике. - М.: Изд. Института психотерапии. 2010. - 414 с.

4. Linehan M. M., Amstrong H. E., Suarez A, Allmon D, Heard H. L. 1991. Cognitive-behavioral treatment of chronically parasuicidal borderline patients. Arch Gen Psychiatry 48: 1060-1064.

5. Linehan M. M., Tutek D. A., Heard H. L., Armstrong H. E. 1994. Interpersonal outcome of cognitive behavioral treatment for chronically suicidal borderline patients. Am J Psychiatry 151: 1771-1776.

6. Linehan M. M. Schmidt H. 3rd, Dimeff L. A., Craft J. C., Kanter J. Comtois K. A. 1999. Dialectical behavior therapy for patients with borderline personality disorder and drug-dependence. Am J Addict 8: 279-292.

7. Linehan M. M., Dimeff L. A., Reynolds S. K., et al. 2002. Dialectical behavior therapy versus comprehensive validation therapy plus 12-step for the treatment of opioid dependent women meeting criteria for borderline personality disorder. Drug Alcohol Depend 67: 13-26.

8. Linehan M. M., Comtois K. A., Murray A. M., et al. 2006. Two-year randomized controlled trial and follow-up of dialectical behavior therapy vs therapy by experts for suicidal behaviors and borderline personality disorder. Arch Gen Psychiatry 63: 757-766.

9. Verheul R, Van Den Bosch L. M., Koeter M. W., De Ridder M. A., Stijnen T., Van Den Brink W. 2003. Dialectical behavior therapy for women with borderline personality disorder: 12-month, randomised clinical trial in the netherlands. Br J Psychiatry 182: 135-140.

10. Bosch L. M., Koeter M. W., Stijnen T., Verheul R., van den Brink W. 2005. Substained efficacy of dialectical behavior therapy for borderline personality disorder. Behav Res Ther 43: 1231-1241.

11. Bateman A., Fonagy P. Randomized controlled trial of outpatient mentalization-based treatment versus structured clinical management for borderline personality disorder. Am. J. Psychiatry. 2009; 166(12): 1355-1364.

12. Bateman A., Fonagy P. Personality Disorders: Theory, Research and Treatment A Randomized Controlled Trial of a Mentalization-Based Borderline Personality Disorder A Randomized Controlled Trial of a Mentalization-Based Intervention (MBT-FACTS) for Families of People With. 2019; 10(1): 70.

13. C., Kalgren L., Sandell A., F., Philips B. Mentalization-based therapy adherence and competence stimulates in-session mentalization in psychotherapy for borderline personality disorder with co-morbid substance dependence. Trials. 2016/07/14 ed. 2017; 27(6): 749-765.

14. Philips B, Wennberg P, Konradsson P, Franck J. Mentalization-Based Treatment for Concurrent Borderline Personality Disorder and Substance Use Disorder: A Randomized Controlled Feasibility Study. Eur Addict Res. 2018/02/07 ed. 2018; 24(1): 1-8.

15. Kvarstein EH, Pedersen G, Folmo E, Urnes , Johansen MS, Hummelen B, et al. Mentalization-based treatment or psychodynamic treatment programmes for patients with borderline personality disorder - the impact of clinical severity. Psychol Psychother Theory Res Pract. 2018. 1-21.

16. Бурно А. А. Практическое руководство по Терапии творческим самовыражением/Под. ред. М. Е. Бурно, Е. А. Добролюбовой. - М.: Академический Проект, ОППЛ, 2003. - С. 342-347.

17. Бурно М. Е. Клиническая психотерапия. Изд. 2-е, доп. и перераб. - М.: Академический проект; Деловая книга, 2006;

18. Иговская А. С. Краткая история клинической психотерапии пациентов со специфическими расстройствами личности с преобладанием ипохондрии//Мед. психология в России. 2012. N 2 (13). - С. 1-4.

19. Кернберг О. Ф. Тяжелые личностные расстройства. Стратегии психотерапии. Severe Personality Disorders: Psychotherapeutic Strategies. - Москва: Независимая фирма " Класс", 2001. - 464 с.

20. Stoffers JM, Vollm BA, Rucker G et al. Pharmacological intervention for borderline personality disorder. Cochrane Database Syst Rev 2010.

21. Ingenhoven T., Lafay P., Rinne T. et al. Effectiveness of pharmacotherapy for severe personality disorders: meta-analyses of randomized controlled trials//J. Clin. Psychiatry. 2010. Vol. 71. P. 14-25.

22. Смулевич А. Б. Расстройства личности. Траектория в пространстве психической и соматической патологии. - М.: МИА, 2012. - 336 с.

23. Gardner D. L., Cowdry R. W.: Alprazolam-induced dyscontrol in borderline personality disorder. Am J Psychiatry 1985; 142: 98-100.

24. Cowdry R. W., Gardner D. L.: Pharmacotherapy of borderline personality disorder: alprazolam, carbamazepine, trifluoperazine, and tranylcypromine. Arch Gen Psychiatry 1988; 45: 111-119.

25. Herpertz SC, Zanarini M, Schulz CS, Siever L, Lieb K, HJ; WFSBP Task Force on Personality Disorders; World Federation of Societies of Biological Psychiatry (WFSBP). World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of personality disorders. World J Biol Psychiatry. 2007; 8(4): 212-44.

26. Арана Дж., Розенбаум Дж. Фармакотерапия психических расстройств. Пер. с англ. М.: " Издательство БИНОМ", 2006. - 416 с.

27. Stahl S. M. Stahl's essential psychopharmacology: neuroscientific basis and practical applications. Cambridge university press, 2013.

28. Alapin B., Stanczak T. Neuleptil (propericiazine) - a correcting drug in behavior disorders. Preliminary report (article in Polish). Neurologia, Neurochirurgiai Psychiatria Polska 1966; 16 (10): 1167-1171;

29. Daneel A. B. Neulactil (pericyazine) in the behaviour disturbances of institutionalized mental defectives. SAJ Med Sci 1967; 41 (39): 995-998;

30. Nardini L, Pistoni A. Selectivity of action of propericiazine in behavior disorders (article in Italian). Rivista Sperimentale Freniatria Medicina Legale Alienazioni Mentali. 1967; 91 (2): 569-575;

31. Nimb M. Proceedings of a symposium on behavioural disorders held in Leeds. Ed. F. A. Jenner. Dagenham, 1965; p. 21;

32. Rasch P. J. Treatment of disorders of character and schizophrenia by pericyazine (Neulactil). Acta Psychiatr Scand. (Suppl. ) 1966; 191: 200-215;

33. Villa J. L., Nouri A. Therapy of personality problems and behavior in the aged with a phenothiazine derivative (neuleptil) (article in French). Praxis 1967; 56 (44): 1500-1510;

34. Volmat R. Proceedings of a symposium on behavioural disorders held in Leeds. Ed. F. A. Jenner. Dagenham, 1965; p. 30; Wallis GG. Proceedings of a symposium on behavioural disorders held in Leeds. Ed. F. A. Jenner. Dagenham, 1965; p. 26;

35. Ionescu R, Nica S. U., Oproiu L. et al. Double-blind study in psychopathic behavior disorders (clozapine and pericyazine). Pharmakopsychiatrie Neuropsychopharmakologie 1973; 6 (6): 294-9.

36. Калинин В. В. Неулептил: применение в клинической практике. Социальная и клиническая психиатрия. 1993; 3(3): 134-138.

37. Данилов Д. С. Эффективность и переносимость терапии перициазином больных шизотипическим расстройством, органическим расстройством личности и пациентов с патохарактерологическими нарушениями в рамках расстройств личности. Журн. неврологии и психиатрии им. C. C. Корсакова. 2017; 117 (10): 65-71.

38. Soloff P. H., Cornelius J., George A., Nathan S., Perel J. M., Ulrich R. F.: Efficacy of phenelzine and haloperidol in borderline personality disorder. Arch Gen Psychiatry 1993; 50: 377-385.

39. Duivenvoorden H. J. Differential effectiveness of antipsychotics in borderline personality disorder: meta-analyses of placebo-controlled, randomized clinical trials on symptomatic outcome domains//Journal of clinical psychopharmacology. - 2011. - Т. 31. - N 4. - С. 489-496.

40. Cornelius J. R., Soloff P. H., Perel J. M., Ulrich R. F.: Continuation pharmacotherapy of borderline personality disorder with haloperidol and phenelzine. Am J Psychiatry 1993; 150: 1843-1848.

41. Rocca P., Marchiaro L., Bogetto F. Treatment of borderline personality disorder with risperidone//The Journal of clinical psychiatry. - 2002. - Т. 63. - N 3. - С. 241-244.

42. Hallmayer J. F. Risperidone and borderline personality disorder//Current psychiatry reports. - 2003. - Т. 5. - N 3. - С. 175-176.

43. Bogenschutz M. P., George Nurnberg H. Olanzapine versus placebo in the treatment of borderline personality disorder. J Clin Psychiatry. 2004; 65: 104-109;

44. Zanarini M. C., Frankenburg F. R. Olanzapine treatment of female borderline personality disorder patients: a double-blind, placebo-controlled pilot study. J Clin Psychiatry. 2001; 62: 849-854.

45. Zanarini M. C., Frankenburg F. R., Parachini E. A. A preliminary, randomized trial of fluoxetine, olanzapine, and the olanzapine-fluoxetine combination in women with borderline personality disorder. J Clin Psychiatry. 2004; 65: 903-907;

46. Linehan M. M., McDavid J. D., Brown M. Z., et al. Olanzapine plus dialectical behavior therapy for women with high irritability who meet criteria for borderline personality disorder: a double-blind, placebo-controlled pilot study. J Clin Psychiatry. 2008; 69: 999-1005;

47. Shafti S. S., Shahveisi B. Olanzapine versus haloperidol in the management of borderline personality disorder: a randomized double-blind trial. J Clin Psychopharmacol. 2010; 30: 44-47;

48. Soler J., Pascual J. C., Campins J., et al. Double-blind, placebo-controlled study of dialectical behavior therapy plus olanzapine for borderline personality disorder. Am J Psychiatry. 2005; 162: 1221-1224.

49. Bogenschutz MP, George Nurnberg H. Olanzapine versus placebo in the treatment of borderline personality disorder. J Clin Psychiatry. 2004; 65: 104-109;

50. Zanarini MC, Frankenburg FR. Olanzapine treatment of female borderline personality disorder patients: a double-blind, placebo-controlled pilot study. J Clin Psychiatry. 2001; 62: 849Y854.

51. Zanarini M. C., Frankenburg F. R., Parachini E. A. A preliminary, randomized trial of fluoxetine, olanzapine, and the olanzapine-fluoxetine combination in women with borderline personality disorder. J Clin Psychiatry. 2004; 65: 903-907.

52. Nickel M. K, Muehlbacher M, Nickel C, et al. Aripiprazole in the treatment of patients with borderline personality disorder: a double-blind, placebo-controlled study. Am J Psychiatry. 2006; 163: 833-838.

53. Nickel M. K. Aripiprazole treatment of patients with borderline personality disorder. J Clin Psychiatry. 2007; 68: 1815-1816.

54. Frankenburg F., Zanarini M. C.: Clozapine treatment of borderline patients: a preliminary study. Compr Psychiatry 1993; 34: 402-405.

55. Benedetti F., Sforzini L., Colombo C., Maffei C., Smeraldi E.: Low-dose clozapine in acute and continuation treatment of severe borderline personality disorder. J Clin Psychiatry 1998; 59: 103-107.

56. Chengappa K. N., Baker R. W.: The successful use of clozapine in ameliorating severe self mutilation in a patient with borderline personality disorder. J Personal Disord 1995; 9: 76-82.

57. Frankenburg F. R., Zanarini M. C. Clozapine treatment of borderline patients: a preliminary study//Comprehensive Psychiatry. - 1993. - Т. 34. - N 6. - С. 402-405.

58. Pascual J. C., Soler J., Puigdemont D., et al. Ziprasidone in the treatment of borderline personality disorder: a double-blind, placebo-controlled, randomized study. J Clin Psychiatry. 2008; 69: 603-608.

59. Tritt K, Nickel C, Lahmann C, et al. Lamotrigine treatment of aggression in female borderline-patients: a randomized, double-blind, placebo-controlled study. J Psychopharmacol. 2005; 19: 287-291.

60. Leiberich P, Nickel MK, Tritt K, et al. Lamotrigine treatment of aggression in female borderline patients. Part II: An 18-month follow-up. J Psychopharmacol. 2008; 22: 805-808.

61. Reich DB, Zanarini MC, Bieri KA. A preliminary study of lamotrigine in the treatment of affective instability in borderline personality disorder. Int Clin Psychopharmacol 2009; 24 (5): 270-5.

62. Loew T. H., Nickel M. K., Muehlbacher M., et al. Topiramate treatment for women with borderline personality disorder: a double-blind, placebo-controlled study. J Clin Psychopharmacol. 2006; 26: 61-66.

63. Nickel M. K., Nickel C., Mitterlehner F. O., et al. Topiramate treatment of aggression in female borderline personality disorder patients: a double-blind, placebo-controlled study. J Clin Psychiatry. 2004; 65: 1515-1519.

64. Nickel M. K., Nickel C., Kaplan P. et al. Treatment of aggression with topiramate in male borderline patients: a double-blind, placebo-controlled study. Biol. Psychiatry. 2005; 57: 495-499;

65. Nickel M. Topiramate reduced aggression in female patients with borderline personality disorder. Eur Arch Psychiatry Clin Neurosci. 2007; 257: 432-433.

66. Nickel MK, Loew TH. Treatment of aggression with topiramate in male borderline patients. Part II: 18-month follow-up. Eur Psychiatry. 2008; 23: 115-117.

67. de la Fuente JM, Lotstra F. 1994. A Trial of carbamazepine in borderline personality disorder. Eur. Neuropsychopharmacol 4: 470-486.

68. Nose M. et al. Efficacy of pharmacotherapy against core traits of borderline personality disorder: meta-analysis of randomized controlled trials//International clinical psychopharmacology. - 2006. - Т. 21. - N 6. - С. 345-353.

69. Vita A., De Peri L., Sacchetti E. Antipsychotics, antidepressants, anticonvulsants, and placebo on the symptom dimensions of borderline personality disorder: a meta-analysis of randomized controlled and open-label trials//Journal of Clinical Psychopharmacology. - 2011. - Т. 31. - N 5. - С. 613-624.

70. Tang T. Z., DeRubeis R. J., Hollon S. D. et al. Personality change during depression treatment: a placebo-controlled trial//Arch. Gen. Psychiatry. 2009. Vol. 66. P. 1322-1330.

71. Salzmann C., Wolfson A. N., Schatzberg A., et al. 1995. Effect of fluoxetine on anger in symptomatic volunteers with borderline personality disorder. J Clin Psychopharmacol 15: 23-29.

72. Coccaro E. F., Kavoussi R. J. 1997. Fluoxetine and impulsive aggressive behaviour in personality-disordered subjects. Arch Gen Psychiatry 54: 1081-1088.

73. Fan A. H., Hassell J. Bipolar disorder and comorbid personality psychopathology: a review of the literature to examine the prevalence of personality disorder comorbidity in bipolar disorder and examine the effects of this comorbidity on bipolar disorder patients//J. Clin. Psychiatry. 2008. Vol. 69, N 11. P. 1794-803.

74. Zanarini M. C., Frankenburg F. R., Parachini E. A. A preliminary, randomized trial of fluoxetine, olanzapine, and the olanzapine-fluoxetine combination in women with borderline personality disorder. J Clin Psychiatry. 2004; 65: 903-907.

75. Ekselius L., von Knorring L. Personality disorder comorbidity with major depression and response to treatment with sertraline or citalopram//Int. Clin. Psychopharmacol. 1998. Vol. 13, N 5. P. 205-211.

76. Soloff P. H., George A., Nathan S., Schulz P. M., Cornelius J. R., Herring J., Perel J. M.: Amitriptyline versus haloperidol in borderlines: final outcomes and predictors of response. J Clin Psychopharmacol 1989; 9: 238-246;

77. Обухов С. Г. Психиатрия/Под ред. Ю. А. Александровского - М.: ГЭОТАР-Медиа, 2007. - 352 с.

78. Смулевич А. Б. Расстройства личности. Рациональная фармакотерапия в психиатрической практике. Руководство для практикующих врачей. - М.: Литтера, 2014. - С. 458-493.

79. Bateman, A. and Fonagy, P. (1999). Effectiveness of partial hospitalization in the treatment of borderline personality disorder: a randomized controlled trial. Am J Psychiatry 156: 1563-1569;

80. Chiesa, M. and Fonagy, P. (2003). Psychosocial treatment for severe personality disorder: 36-month follow-up. Br J Psychiatry 183: 356-362.

81. Spong A. J. et al. Brief psychological interventions for borderline personality disorder. A systematic review and meta-analysis of randomised controlled trials//Clinical psychology review. - 2020. - С. 101937.

82. Gibbon S. et al. Psychological interventions for antisocial personality disorder//Cochrane Database of Systematic Reviews. - 2020. - N 9.

83. McLaughlin S. P. B. et al. Group psychotherapy for borderline personality disorder: A meta-analysis of randomized-controlled trials//Psychotherapy. - 2019. - Т. 56. - N 2. - С. 260.

84. Cristea I. A. et al. Efficacy of psychotherapies for borderline personality disorder: a systematic review and meta-analysis//Jama psychiatry. - 2017. - Т. 74. - N 4. - С. 319-328.

85. Barnicot K. et al. Treatment completion in psychotherapy for borderline personality disorder - a systematic review and meta-analysis//Acta Psychiatrica Scandinavica. - 2011. - Т. 123. - N 5. - С. 327-338.

86. Kliem S., C., Kosfelder J. Dialectical behavior therapy for borderline personality disorder: a meta-analysis using mixed-effects modeling//Journal of consulting and clinical psychology. - 2010. - Т. 78. - N 6. - С. 936.

87. Oud M. et al. Specialized psychotherapies for adults with borderline personality disorder: a systematic review and meta-analysis//Australian & New Zealand Journal of Psychiatry. - 2018. - Т. 52. - N 10. - С. 949-961.

88. Chakhssi F. et al. Effect of psychotherapy for borderline personality disorder on quality of life: a systematic review and meta-analysis//Journal of personality disorders. - 2021. - Т. 35. - N 2. - С. 255-269.

89. Wilson H. A. Can antisocial personality disorder be treated? A meta-analysis examining the effectiveness of treatment in reducing recidivism for individuals diagnosed with ASPD//International Journal of Forensic Mental Health. - 2014. - Т. 13. - N 1. - С. 36-46.

90. Oltmanns J. R. et al. General factors of psychopathology, personality, and personality disorder: Across domain comparisons//Clinical psychological science. - 2018. - Т. 6. - N 4. - С. 581-589.

91. Derksen J., Sloore H. Psychodiagnostics and Indications for Treatment in Cases of Personality Disorder//Treatment of personality disorders. - Springer, Boston, MA, 1999. - С. 155-166.

Приложение А1

⇐ Предыдущая 1 2 3 4 567 8 9 10 Следующая ⇒

Воспользуйтесь поиском по сайту: